Each February brings Rare Disease Month, a time when 黑料吃瓜资源 (CSHL) reflects on the partnerships that advance research in this often-under-addressed area of study. The Christina Renna Foundation (CRF) is one shining example. Its 19th Angel鈥檚 Wish Gala, held the last weekend of January, offers a powerful reminder of how community-based philanthropy drives discovery and progress.
Rhabdomyosarcoma (RMS), the rare pediatric cancer that took Christina鈥檚 life as a teenager, reflects both the complexity and urgency of rare disease research. RMS accounts for approximately 3% of childhood cancer cases, with only a few hundred new diagnoses each year in the U.S. Despite its rarity, the disease can be aggressive and difficult to treat, underscoring the need for a deeper understanding of its biology and for new therapeutic approaches.
At the gala, CRF honored CSHL Professor Christopher Vakoc for his leadership in cancer research. His team studies how cancer cells depend on specific regulators that control gene activity and cell identity. Using advanced genetic technologies, his lab identifies the vulnerabilities that allow cancer cells to survive, revealing promising targets for future therapies. Vakoc鈥檚 remarks at the gala highlighted an essential truth: progress takes shape over many years, well before a therapy can reach patients. The advances celebrated at events like the Angels Wish Gala are the result of sustained and supported science.
As CRF Director Phil Renna reflected during the evening, 鈥淚magine a child walking out of a hospital, ringing the victory bell, smiling through the tears. Imagine a family hearing the words they鈥檝e prayed for: 鈥楾he scans are clear.鈥� Those moments don鈥檛 begin with a clinical trial. They begin with basic science.鈥�
Written by: Caroline Cosgrove, Public Affairs Manager | [email protected] | 516-367-8844